Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fields of Urology, Immunology including Transplantation and Infectious Diseases, Oncology, Neuroscience and DM Complications and Metabolic Diseases. With over 17,000 global employees, Astellas researches, develops, manufactures, and promotes its prescription drugs through subsidiaries in the US, Europe, and Asia

Notice Regarding Foreign Exchange Loss

Presentation Material For Information Meeting (Q2 Ytd/Fy2024)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Astellas Pharma (4503 JP)

Notice Regarding Foreign Exchange Loss

Presentation Material For Information Meeting (Q2 Ytd/Fy2024)

Financial Results (Q2 Ytd/Fy2024)

Supplementary Documents (Q2 Ytd/Fy2024)

Astellas Provides Update On Marketing Authorization Application For Avacincaptad Pegol (Acp) In The European Union

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)